All In Biotech

Drug Trial Radar · NCT06230822

Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)

A Phase I Open Label, Dose Escalation Study to Characterize the Safety, Tolerability, and Efficacy of VUM02 Injection in Subjects With Idiopathic Pulmonary Fibrosis

Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

9

Actual

Start

Mar 5, 2024

Primary completion

Mar 13, 2025

Study completion Aug 1, 2025

Sponsor

Sponsor type
Industry
First posted
Jan 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a single-arm, multiple-dose, dose-escalation, open-label multicenter clinical trial, aiming to evaluate the safety, tolerability, and preliminary efficacy of VUM02 Injection for treatment of idiopathic pulmonary fibrosis (IPF). VUM02 Injection (Human Umbilical Cord Tissue-derived Mesenchymal Stem Cells Injection, hUCT-MSC) is an allogeneic cell therapy product comprising culture-expanded Mesenchymal Stem Cells derived from the human umbilical cord tissue. The product is cryopreserved with the amount of 5 x 10\^7 cells per 10 mL per bag (5 x 10\^6 cells/mL). This study is a multiple-dose tolerability study following the "3+3" dose escalation principle and progressing from the low-dose group to the high-dose group sequentially. Three to six patients will be enrolled in each dose group and administered every 3 days for a total of 3 doses.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • VUM02 InjectionDrug

    VUM02 Injection will be administered intravenously every 3 days for a total of 3 doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of cell therapy-related adverse events (AEs) as assessed by CTCAE (V5.0)Time frame: 28 days
  2. Maximum tolerated dose (MTD)Time frame: 28 days

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University Third Hospital

    Beijing, China

  • West China Hospital of Sichuan University

    Chengdu, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, China

  • The First People's Hospital of Kashi Prefecture, Xinjiang

    Kashgar, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.